Search results
Results from the WOW.Com Content Network
Side effects from taking glimepiride include gastrointestinal tract (GI) disturbances, occasional allergic reactions, and rarely blood production disorders including thrombocytopenia, leukopenia, and hemolytic anemia. In the initial weeks of treatment, the risk of hypoglycemia may be increased.
[2] [1] It contains the thiazolidinedione pioglitazone and the sulfonylurea glimepiride. [2] [1] It is taken by mouth. [2] [1] The most common side effects include upper respiratory tract infections (such as colds), hypoesthesia (reduced sense of touch), bone fractures, weight gain, dizziness, flatulence (gas) and edema (swelling). [1]
Adverse effects include nasopharyngitis, headache, nausea, heart failure, hypersensitivity and skin reactions. [citation needed] The U.S. Food and Drug Administration (FDA) is warning that the type 2 diabetes medicines like sitagliptin, saxagliptin, linagliptin, and alogliptin may cause joint pain that can be severe and disabling.
Besides these metabolic effects, GLP-1 drugs also appear to have an impact on brain health and mental health. ... “Overall, serious side effects, such as suicidal ideations are very rare.” ...
As interest in taking glucagon-like peptide-1 receptor agonist (GLP-1 agonist) medications, such as Zepbound and Wegovy, for weight loss, research continues to examine potential new side effects ...
This weak evidence for adverse effects has reduced the use of rosiglitazone, despite its important and sustained effects on glycemic control. [23] Safety studies are continuing. In contrast, at least one large prospective study, PROactive 05, has shown that pioglitazone may decrease the overall incidence of cardiac events in people with type 2 ...
For all the buzz surrounding weight loss medications like semaglutide and tirzepatide, these drugs aren’t perfect. They come with a risk of side effects like nausea and diarrhea, along with ...
Common adverse effects over 10%: [13] Hypoglycemia (11 - 12%) - while it was shown to have the same efficacy as glimepiride, one of the newer sulfonylureas, the European GUIDE study has shown that it has approximately 50% less hypoglycemic confirmed episodes in comparison with glimepiride. [14] Uncommon adverse effect between 1 - 10%: [13]